Cellectar biosciences reports financial results for q2 2024 and provides a corporate update

Florham park, n.j., aug. 13, 2024 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended june 30, 2024, and provided a corporate update.
CLRB Ratings Summary
CLRB Quant Ranking